How etamsylate affects blood clotting in dogs

Abstract

INTRODUCTION: The mechanism of etamsylate on capillary bleeding and its influence on hemostasis is not yet fully understood. This study aims to evaluate the effects of etamsylate on thromboelastographic parameters, platelet count, clotting times and fibrinogen, and its adverse events in dogs. METHODS: Dogs included in this prospective, non-randomized, single-arm interventional study with comparative analysis between clinical groups were divided into dogs without coagulopathies undergoing procedures with high risk of bleeding (&#x202f;=&#x202f;10), dogs with bleeding due to trauma or coagulopathy (&#x202f;=&#x202f;10), and thrombocytopenic dogs with a platelet count <80 &#xd7; 10/l (&#x202f;=&#x202f;10). Dogs that had previously received drugs or fluids influencing hemostasis were excluded. Blood samples were collected for clotting times, platelet count, thromboelastography, and fibrinogen analysis before and 90&#x202f;min after etamsylate administration (12.5&#x202f;mg/kg IV). RESULTS: Thromboelastographic parameters, platelet count, clotting time, and fibrinogen concentrations did not change after treatment with etamsylate in the entire study population and in subgroup analyses. No adverse events of etamsylate were observed. DISCUSSION: In the present study, no effect of etamsylate on hemostasis in dogs could be detected using coagulation parameters. Further studies using methods that incorporate the function of the vascular endothelium are necessary.